drugset / Trial / NCT03114631
Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer
Phase 1/2
Completed
30 enrolled
The Republican Research and Practical Center for Epidemiology and Microbiology
Belarusian State Medical University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The trial evaluates the safety and efficacy of MUC-1/WT-1 peptide and/or tumor lysate-pulsed dendritic cell Immunotherapy for the patients with pancreatic cancer
Timeline
- Start
- 2017-01-09
- Primary completion
- 2019-05-03
- Completion
- 2019-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendritic cells pulsed with MUC-1/WT-1 peptides | Cell therapy | — | Subcutaneous |
| Subject | Dendritic cells pulsed with tumor lysate | Cell therapy | — | Subcutaneous |